May 19, 2017 02:44 PM EDT
A recent research had discovered that eating a nut filled diet could improve bowel cancer survival by 57 percent. Aside from that, another study that will be presented at the meeting of the American Society of Clinical Oncology next month was reported to have stage 3 colon cancer patients to less likely die by 42 percent.
According to Mail Online, the study had discovered that Tree nuts which include almonds, pecans and walnuts have the biggest benefits to colon cancer patients. The reason why tree nuts are healthy for patients is that it contains high amounts of healthy fatty acids, fiber, and flavonoids. However, peanuts and peanut butter do not count as the kind of nuts that people with the disease should eat as a snack.
The study funded by the U.S. National Institutes of Health was said to include 800 patients who had received surgery and chemotherapy for their colon cancer. In which, those who have eaten nuts were found to have a 57 percent lower risk of premature death compared to those who didn’t eat.
With that said, the study lead by Dr. Temidayo Fadelu discovered that the difference between the benefits of tree and peanuts lies on both of their different biochemical compositions. It was then believed by the team that those patients that benefited from eating tree nuts have blood sugar and low levels of insulin. In which was stated that it could decrease their colon cancer risk indeed.
The second study was stated to be focused on stage 3 colon cancer patients after chemotherapy as CBS News reported. The patients who are following the American Cancer Society guidelines were explained to have a 42 percent less likely to die compared to those who didn’t follow. It was then mentioned that the findings could also apply to other types of cancers.
"We found that patients who maintain a healthy body weight, engage in regular physical activity, and eat a diet rich in vegetables and whole grains and low in red meats and processed meats did better and survived longer than those who didn't," Dr. Erin Van Blarigan of the University of California, San Francisco and lead author of the study concluded.